Cadrenal Therapeutics (CVKD) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Cadrenal Therapeutics in October 2026.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
